A review of discontinuing buprenorphine for opioid use disorder restates the central fact first: the drug more than halves both overdose risk and all-cause mortality, so staying on it is protective and stopping it carries risk.

When discontinuation is pursued, the evidence favours caution. Longer maintenance — beyond 12 months — and slow, individualised tapers of about 2 mg per month or less are associated with lower overdose risk, less return to opioid use and higher rates of completing the taper. Adjunctive medication for withdrawal, naloxone provision and continued follow-up all help. The optimal duration of maintenance is unknown, so the decision to stop should be clinically supported, patient-centred and voluntary — and for some, a sustained lower dose is a better endpoint than full cessation.

The practice change is to resist patient-driven abrupt stops: frame buprenorphine as protective, taper slowly if at all, and keep naloxone and follow-up in place throughout.

Buprenorphine more than halves overdose and all-cause mortality — treat staying on it as protective.
If stopping, taper slowly (about 2 mg per month or less) rather than abruptly.
Longer maintenance beyond 12 months is linked to lower overdose risk and less relapse.
Keep naloxone and follow-up in place, and accept a sustained lower dose as a valid endpoint.

Why it matters

It counters the instinct to treat discontinuation as the goal, when stopping — especially abruptly — is itself the main risk.

Don't overread it

The taper-rate and maintenance-duration evidence is observational, and the optimal duration of therapy is unknown — this guides how to stop, not a mandate about when.